OakChart

ANI Pharmaceuticals Inc

ANIPHealthcare·Drug Manufacturers - Specialty & Generic·USA·Small·NASD·Nov 11 • 12:55 PM ET

71.69+0.44 (0.62%)
2026-11-11 18:56 CET
Market cap
1,636.64 USD m
Revenue, TTM
1,041.34 USD m
Net income, TTM
108.53 USD m
Free cash flow, TTM
205.32 USD m
EPS diluted, TTM
5.01
P/E
14.31
Compare

Price

ANIP against its 20, 50 and 200-day averages
2050200beatmiss
70.0075.0080.0085.00654K1.3MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ANIPclose 71.6920-day 71.5750-day 72.38200-day 77.1171.6952w low

21.0% under the 52-week high of 90.73 on 11 Nov 2025. 52-week low 67.14 on 6 Nov 2026. Last 15 sessions, 13.2% high to low

Profile

ANIP
52-week range, 19% of the way up
67.1490.73

ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. It operates through the Generics, Established Brands, and Other, and Rare Disease segments. The Generics, Established Brands, and Other segment consists of contract manufactured products, development services, royalties, and other. The Rare Disease segment involves the operations related to Cortrophin Gel. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.

IndexRUT
Employees970
IPOMay 12, 2000
Beta0.47
ATR, 14d2.45
Rel volume0.78
Short float17.76%
Insider own12.13%
Inst own100.78%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap1.65B
Enterprise Value1.82B
Income108.53M
Sales1.04B
Book/sh27.82
Cash/sh19.00
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees970
IPOMay 12, 2000

Ratios

P/E14.31
Forward P/E7.04
PEG0.53
P/S1.58
P/B2.58
P/C3.77
P/FCF8.02
EV/EBITDA7.50
EV/Sales1.75
Quick Ratio2.33
Current Ratio2.75
Debt/Eq0.95
LT Debt/Eq0.92
Option/ShortYes / Yes

Earnings

EPS (ttm)5.01
EPS next Y10.19
EPS next Q2.58
EPS this Y20.03%
EPS next Y7.61%
EPS next 5Y13.16%
EPS past 3/5Y- -
Sales past 3/5Y40.81% 33.48%
EPS Y/Y TTM203.25%
Sales Y/Y TTM25.94%
EPS Q/Q33.23%
Sales Q/Q27.64%
EarningsNov 05 BMO
EPS/Sales Surpr.23.64% 3.63%

Ownership

Insider Own12.13%
Insider Trans-4.08%
Inst Own100.78%
Inst Trans-2.26%
ROA7.29%
ROE18.99%
ROIC8.89%
Gross Margin53.11%
Oper. Margin15.32%
Profit Margin10.42%
SMA200.17%
SMA50-0.94%
SMA200-7.02%
Trades-

Technical

Shs Outstand22.89M
Shs Float20.18M
Short Float17.76%
Short Ratio8.83
Short Interest3.58M
52W High90.73 -20.98%
52W Low67.14 6.79%
Volatility5.45% 3.31%
ATR (14)2.45
RSI (14)50.28
Beta0.47
Rel Volume0.78
Avg Volume405.83K
Volume174,749

Performance

Perf Week0.06%
Perf Month1.21%
Perf Quarter-4.11%
Perf Half Y-11.36%
Perf YTD-9.18%
Perf Year-19.03%
Perf 3Y37.45%
Perf 5Y58.20%
Perf 10Y24.53%
Recom1.62
Target Price103.38
Prev Close71.25
Price71.69
Change %0.62%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Sep 23, 2026InitiatedOOppenheimerPerform
Sep 09, 2026InitiatedLLeerink PartnersOutperform$104+45.1%
Jul 17, 2026InitiatedCCanaccord GenuityHold$91+26.9%
Jul 10, 2025InitiatedHH.C. WainwrightBuy$84+17.2%
Mar 14, 2025InitiatedJJefferiesBuy$80+11.6%
Mar 12, 2025InitiatedJJP MorganOverweight$85+18.6%
Dec 11, 2024InitiatedLLeerink PartnersOutperform$80+11.6%
Oct 11, 2024InitiatedPPiper SandlerOverweight$68-5.2%
Mar 15, 2024InitiatedCCapitalOneOverweight$80+11.6%
Aug 22, 2023ReiteratedHH.C. WainwrightBuy$60 → $73+1.8%

Peers

Mkt cap
TickerCompanyMkt cap
AMRXAmneal Pharmaceuticals Inc7.63B
AMPHAmphastar Pharmaceuticals Inc1.24B
BHCBausch Health Companies Inc3.15B
ETONEton Pharmaceuticals Inc2.02B
HROWHarrow Inc1.10B
RDYDr. Reddy's Laboratories Ltd ADR12.28B
VTRSViatris Inc24.04B
TEVATeva- Pharmaceutical Industries Ltd49.97B
COLLCollegium Pharmaceutical Inc767.40M
EYPTEyePoint Inc31.44M

Insider trading

latest 14 of 68
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
CAREY STEPHEN P.SVP & CFOOct 29 '26Sale72.872,850207,680166,143Oct 30 04:36 PM
STEPHEN CAREYOfficerOct 29 '26Proposed Sale71.718,550613,120Oct 29 04:20 PM
Lalwani NikhilPRESIDENT & CEOOct 15 '26Sale71.895,400388,206333,689Oct 16 06:50 PM
NIKHIL LALWANIDirectorOct 15 '26Proposed Sale70.165,400378,864Oct 15 04:25 PM
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.Oct 13 '26Sale73.5950036,79573,424Oct 13 08:47 PM
CAREY STEPHEN P.SVP & CFOSep 29 '26Sale73.002,850208,050168,993Sep 30 04:52 PM
Lalwani NikhilPRESIDENT & CEOSep 15 '26Sale71.005,400383,400339,089Sep 16 04:20 PM
NIKHIL LALWANIDirectorSep 15 '26Proposed Sale70.405,400380,160Sep 15 04:24 PM
Thoma JeanneDirectorSep 11 '26Sale71.531,00071,53026,762Sep 14 08:57 PM
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.Sep 14 '26Sale70.7950035,39573,924Sep 14 08:56 PM
JEANNE THOMADirectorSep 11 '26Proposed Sale71.461,00071,460Sep 11 04:33 PM
CAREY STEPHEN P.SVP & CFOAug 31 '26Sale72.802,850207,480171,843Sep 01 06:18 PM
Lalwani NikhilPRESIDENT & CEOAug 25 '26Sale74.305,400401,220344,489Aug 26 06:15 PM
NIKHIL LALWANIDirectorAug 25 '26Proposed Sale74.175,400400,518Aug 25 04:42 PM

Held by

AUM
TickerCompanyAUM
IJRiShares Core S&P Small-Cap ETFAUM: 106.27B
AVUVAvantis U.S. Small Cap Value ETFAUM: 32.39B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
PJPInvesco Pharmaceuticals ETFAUM: 603.92M
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
DFATU.S. Targeted Value Portfolio-ETF Class Shares-
SPSMState Street SPDR Portfolio S&P 600TM Small Cap ETFAUM: 16.06B
IJTiShares S&P Small-Cap 600 Growth ETFAUM: 7.45B

News

latest 14 of 206
  • Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down (BioPharma Dive)
  • ANI Pharmaceuticals Beats On Diversified Strength, But A Second Cortrophin Guidance Cut Overshadows The Egetis Deal (Earnings Whispers)
  • ANI: Q3 Earnings Snapshot (Associated Press)
  • ANI Pharmaceuticals Reports Third Quarter 2026 Financial Results (GlobeNewswire)
  • REPEAT - ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business (GlobeNewswire)
  • Loading…
  • ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business (GlobeNewswire)
  • ANI Pharmaceuticals to Present at Upcoming November Investor Conferences (GlobeNewswire)
  • ANI Pharmaceuticals Needs Cortrophin To Hit Its Trimmed Third-Quarter Guide As The Gout Launch Faces Scrutiny (Earnings Whispers)
  • ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ET (GlobeNewswire)
  • ANI Pharmaceuticals Announces the Launch of Duloxetine Delayed-Release Capsules (GlobeNewswire)
  • ANI Pharmaceuticals Announces Positive Phase 4 Open-Label, Single-Arm SYNCHRONICITY Clinical Trial Results Presented as Late Breaking Oral Presentation at the American Academy of Ophthalmology 2026 Annual Meeting (GlobeNewswire)
  • ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting (GlobeNewswire)
  • ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-052.7002.1841.510290.78280.598
2026Q22026-08-072.2102.0431.052266.04260.138
2026Q12026-05-082.0501.2991.276237.46207.638
2025Q42026-02-272.3301.9921.172247.06231.098
2025Q32025-11-072.0401.7701.133227.81212.848
2025Q22025-08-081.8001.4060.361211.37190.127
2025Q12025-05-091.7001.3830.686197.12180.648
2024Q42025-02-281.6301.435-0.549190.57175.366
2024Q32024-11-081.3401.086-1.266148.33144.375
2024Q22024-08-061.0200.950-0.139138.04129.095
2024Q12024-05-101.2100.9960.825137.43126.035
2023Q42024-02-291.0000.8550.039131.65124.944
2023Q32023-11-081.2700.8430.499131.8111.923
2023Q22023-08-091.2800.6670.327116.5599.873
2023Q12023-05-081.1700.3520.063106.7983.505
2022Q42023-03-090.7600.672-0.28594.2386.045

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY5.0605.1630.498206.55210.37
2020FY3.5003.647-1.885208.48205.37
2021FY3.2103.460-3.397216.14211.6
2022FY1.3601.368-3.046316.39306.9
2023FY4.7104.5230.943486.82479.84
2024FY5.2005.007-1.043614.38599.19
2025FY7.8907.5373.320883.37867.39
2026FY-9.470--1,098
2027FY-10.191--1,214
2028FY-11.432--1,308
2029FY-12.232--1,365
2030FY-12.225--1,430

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-06707303.61295.1312
2026Q4S2026-11-05706304.54295.1318.54
2026Q4S2026-11-04700319.53311.6324.43
2026Q4S2026-10-24801319.21311.6324.43
2026Q4S2026-10-21802319.21311.6324.43
2026Q4S2026-10-02805319.27311.6324.43
2026Q4S2026-09-22804319.93311.6324.62
2026Q4S2026-08-10704319.39311.6324.62
2026Q4S2026-08-07703320.69311.6326.7
2026Q4S2026-07-22701326.49320337.7
2026Q4S2026-07-20712326.34320337.7
2026Q4S2026-07-16712326.34320337.7
2026Q4S2026-07-15712325.91319337.7
2026Q4S2026-07-13612325.3319337.7

Estimate history

EPS, annual-0.091.3030.498-1.885-3.397-3.0460.943-1.0433.3245.009
Period201720182019202020212022202320242025TTM
EPS, quarterly-1.266-0.5490.6860.3611.1331.1721.2761.0521.51
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual176.842201.576206.547208.475216.136316.385486.816614.376883.3661041.34
Period201720182019202020212022202320242025TTM
Sales, quarterly148.332190.574197.122211.371227.813247.06237.462266.044290.777
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual11.66111.86212.112.36516.84117.50520.47821.11922.50222.901
Period201720182019202020212022202320242025MRQ
Shares, quarterly21.08121.11921.67321.73122.47322.50222.88822.97222.901
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue1,041.34883.37614.38486.82316.38216.14208.47206.55201.58
Cost of Goods Sold Incl. D&A488.26432.73317.94241.30195.76147.86131.79103.17106.77
Gross Profit553.08450.64296.44245.51120.6368.2776.68103.3894.81
Selling, General and Administrative Excl. Other393.57369.41294.22195.98146.3696.4492.2582.3658.12
Research and Development50.6051.6644.5834.2922.3212.1527.2626.5114.05
Other Operating Expense0.000.000.000.000.000.000.004.600.00
Operating Income159.5181.232.2249.53-25.73-28.17-15.5716.4336.69
Interest Expense30.5932.5633.6326.9425.757.125.5512.6714.56
Unusual Expense-13.80-33.078.142.5611.8516.424.350.071.53
Net Income Before Taxes157.8495.79-22.2119.87-62.66-56.06-25.963.1620.05
Income Taxes41.0017.45-3.691.09-14.77-13.46-3.41-2.944.56
Consolidated Net Income108.5371.37-18.5218.78-47.90-42.60-22.556.0015.34
Net Income From Continuing Operations108.5371.37-18.5218.78-47.90-42.60-22.556.0015.34
Net Income108.5370.22-20.1517.15-49.52-42.79-22.556.0015.34
EPS (Recurring)4.572.23-0.751.04-2.54-2.48-1.630.501.39
EPS (Basic, Before Extraordinaries)5.173.50-1.040.95-3.05-3.40-1.880.511.31
EPS (Diluted)5.013.32-1.040.94-3.05-3.40-1.880.501.30
EBITDA242.23172.6569.95109.3231.2419.0829.0761.0470.44
Non-Operating Income (Expense)15.1214.0517.34-0.160.67-4.34-0.49-0.53-0.55
Other After Tax Adjustments-8.31-6.960.000.000.000.000.00-0.10-0.15
Stock Option Compensation Expense40.5336.5326.5416.3212.907.669.447.825.28
Price To Earnings Ratio14.2214.22-91.43---126.0134.55
Price To Sales Ratio1.511.901.742.062.072.691.673.592.63
Gross Margin53.1151.0148.2550.4338.1331.5936.7850.0547.03
Operating Margin15.329.200.3610.17-8.13-13.03-7.477.9518.20
Net Margin10.427.95-3.283.52-15.65-19.80-10.822.907.61
Shares Outstanding22.9022.5021.1220.4817.5116.8412.3712.1011.86
Market Capitalization1,636.641,636.641,162.471,126.93702.60771.96358.89745.65533.84

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue290.78266.04237.46247.06227.81211.37197.12190.57
Cost of Goods Sold Incl. D&A131.08119.80114.50122.88116.0297.9095.93102.88
Gross Profit159.69146.25122.96124.18111.79113.47101.1987.69
Selling, General and Administrative Excl. Other107.86106.4184.2595.0588.9698.3187.0986.36
Research and Development13.0014.7510.6012.2612.3016.5410.5616.65
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income51.8439.8438.7129.1322.8315.1714.101.33
Interest Expense7.597.507.557.964.738.228.116.01
Unusual Expense-0.50-1.36-5.93-6.00-16.840.94-11.177.70
Net Income Before Taxes49.0437.1040.2231.4833.8010.5319.99-13.76
Income Taxes13.8912.3910.733.997.181.984.31-3.49
Consolidated Net Income32.7223.0027.4325.3924.137.7314.12-10.28
Net Income From Continuing Operations32.7223.0027.4325.3924.137.7314.12-10.28
Net Income32.7223.0027.4325.3923.797.3213.71-10.68
EPS (Recurring)1.491.011.080.980.570.390.30-0.27
EPS (Basic, Before Extraordinaries)1.541.091.311.231.190.370.70-0.55
EPS (Diluted)1.511.051.281.171.130.360.69-0.55
EBITDA71.3959.4859.6251.7445.4638.4536.9923.93
Non-Operating Income (Expense)4.293.393.134.31-1.154.522.82-1.38
Other After Tax Adjustments-2.43-1.71-2.06-2.10-2.48-0.82-1.560.00
Stock Option Compensation Expense9.199.018.0514.287.667.597.018.94
Price To Earnings Ratio14.2221.0022.9448.41----
Price To Sales Ratio1.511.851.791.952.341.771.991.75
Gross Margin54.9254.9751.7850.2649.0753.6951.3446.02
Operating Margin17.8314.9716.3011.7910.027.187.150.70
Net Margin11.258.6511.5510.2810.443.466.96-5.61
Shares Outstanding22.9022.9722.8922.5022.4721.7321.6721.12
Market Capitalization1,636.641,882.871,724.481,773.711,987.691,413.451,457.741,162.47

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments294.75151.20221.1253.23100.307.8662.3343.0131.14
Short Term Receivables281.08221.73162.08165.44128.5395.7972.1364.8458.79
Inventories143.07136.78111.20105.3681.6960.8048.1640.5037.73
Other Current Assets34.0218.7525.2219.9311.065.564.874.123.75
Total Current Assets752.92528.46519.62343.96321.57170.02187.50152.48131.41
Net Property, Plant & Equipment62.4856.8644.5943.2552.6741.2740.5538.0920.40
Total Investments and Advances1.604.900.008.765.005.005.035.025.01
Intangible Assets542.01601.82237.23279.86322.01192.09183.97205.18231.63
Deferred Tax Assets69.0785.1190.7191.4477.4359.2945.3827.9622.67
Other Assets12.317.3212.272.902.401.101.421.871.03
Total Assets1,440.381,284.47904.42770.16781.09468.78463.84430.60412.14
Short Term Debt Incl. Current Port. of LT Debt19.309.170.851.531.2413.3710.14115.723.35
Accounts Payable62.5845.6636.6829.3022.9711.2614.618.883.63
Income Tax Payable2.247.528.16-0.003.910.005.020.00
Other Current Liabilities194.00132.1099.7868.6063.3350.0336.9335.9232.24
Total Current Liabilities278.11194.45145.4899.4487.5478.5661.68165.5539.23
Long Term Debt608.99639.77314.48287.05287.51172.62176.1067.30198.15
Provision for Risks Charges0.000.000.0035.0631.000.000.000.000.00
Deferred Tax Liabilities---10.079.497.597.05--
Other Liabilities12.5546.5711.720.006.8114.316.220.500.00
Total Liabilities899.65880.79471.67431.62422.35273.08251.05233.34237.38
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.0024.8524.850.000.000.000.00
Common Equity540.72403.68432.75313.69333.89195.70212.79197.26174.76
Total Shareholders Equity540.72403.68432.75338.54358.74195.70212.79197.26174.76
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity540.72403.68432.75338.54358.74195.70212.79197.26174.76
Total Liabilities & Stockholders Equity1,440.381,284.47904.42770.16781.09468.78463.84430.60412.14
Book Value Per Share24.0319.1121.1317.9219.8315.8317.5916.6314.99
Tangible Book Value Per Share-0.06-9.389.551.930.710.292.38-0.67-4.88
Full-Time Employees970897642600601369338299173
Price to Book Ratio2.562.872.622.252.321.833.512.714.11
Return on Assets5.24-1.692.24-6.18-6.82-4.841.343.64-0.29
Return on Equity15.12-4.434.87-13.74-15.37-11.042.928.25-0.62
Return on Invested Capital6.21-1.782.51-7.66-6.59-6.121.545.80-0.29
Quick Ratio2.192.012.812.402.741.392.260.682.39
Current Ratio2.712.723.573.463.672.163.040.923.35

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income116.8478.34-18.5218.78-47.90-42.60-22.556.0915.49
Depreciation82.7291.4267.7359.7959.6547.2544.6444.6133.74
Other Funds (Non Cash)32.648.3647.9127.2723.5915.5119.0118.6415.48
Funds from Operations228.96192.3575.2094.1020.103.4127.8960.2159.53
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital0.23-7.12-11.1924.86-51.30-0.08-12.63-14.585.97
Income Taxes Payable18.23-15.53-1.4211.99-0.16-7.574.98-6.106.18
Cash from Operating Activities229.20185.2264.02118.96-31.203.3215.2745.6365.50
Capital Expenditures-29.28-34.32-16.95-18.51-16.45-23.64-68.32-27.55-10.91
Net Assets From Acquisitions0.000.00-401.280.00-0.03-84.490.000.00-16.47
Sale of Fixed Assets and Businesses0.000.0013.510.000.752.650.000.00-
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00-
Cash from Investing Activities-29.28-34.32-404.72-18.51-15.74-105.48-68.32-27.55-27.38
Cash Dividends Paid0.00-1.16-1.62-1.62-1.62-0.190.000.000.00
Change in Capital Stock-24.321.40-4.4784.56-0.5095.76-0.914.712.32
Repurchase of Common Pref Stock-29.09-12.21-10.96-4.99-1.96-0.89-1.52-1.03-0.66
Sale of Common Pref Stock4.7713.606.4989.551.4696.650.625.742.98
Proceedsfrom Stock Options0.000.000.0080.560.0094.580.000.000.00
Issuance or Reduction of Debt, Net-16.25-10.16327.87-3.00-3.0099.02-0.53-3.46-28.94
Change in Long Term Debt-16.25-10.16327.87-3.00-3.0099.02-0.53-3.46-28.94
Issuance of Long Term Debt0.000.00623.900.000.00310.0315.00118.000.00
Reduction of Long Term Debt-16.25-10.16-296.03-3.00-3.00-211.01-15.53-121.46-28.94
Net Financing Active Other Cash Flow-0.16-0.03-56.83-12.500.000.000.000.000.38
Other Financing Activities Uses-0.16-0.03-56.83-12.500.00---0.00
Cash from Financing Activities-40.73-9.94264.9467.44-5.13194.59-1.441.25-26.24
Exchange Rate Effect-1.04-0.23-0.47------
Net Change in Cash158.15140.73-76.23167.89-52.0792.43-54.4919.3311.88
Free Cash Flow205.32171.3947.78110.09-40.08-20.329.1339.0059.76
Preferred Dividends (Cash Flow)--1.16-1.62-1.62-1.62-0.190.000.000.00
Price to Free Cash Flow7.679.8423.149.25--38.0519.048.87
Deferred Taxes & Investment Tax Credit-14.24-21.91-11.74-15.25-16.75-13.21-9.13-5.18

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments436.38375.87326.10294.75271.50223.55
Short Term Receivables304.45274.47255.43281.08252.62225.65
Inventories136.41143.15143.47143.07146.47138.31
Other Current Assets25.3831.7421.8934.0227.6114.81
Total Current Assets902.62825.23746.88752.92698.20602.33
Net Property, Plant & Equipment81.5573.2267.1162.4863.5659.25
Total Investments and Advances0.001.101.501.602.802.80
Intangible Assets495.59512.34529.64542.01562.30580.85
Deferred Tax Assets74.6771.5066.5669.0771.4092.03
Other Assets13.2310.7210.2812.319.905.75
Total Assets1,567.661,494.111,421.971,440.381,408.151,343.00
Short Term Debt Incl. Current Port. of LT Debt23.3621.3319.3019.3015.2413.22
Accounts Payable74.4273.8369.6962.5869.8054.57
Income Tax Payable8.983.535.302.240.003.29
Other Current Liabilities221.96184.96145.22194.00185.52165.76
Total Current Liabilities328.72283.65239.51278.11270.56236.84
Long Term Debt583.87589.16594.46608.99616.34633.20
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities17.9624.0825.7012.5515.4436.21
Total Liabilities930.55896.90859.67899.65902.34906.24
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity637.11597.21562.30540.72505.82436.76
Total Shareholders Equity637.11597.21562.30540.72505.82436.76
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity637.11597.21562.30540.72505.82436.76
Total Liabilities & Stockholders Equity1,567.661,494.111,421.971,440.381,408.151,343.00
Book Value Per Share27.8226.0024.5724.0322.5120.10
Tangible Book Value Per Share6.183.691.43-0.06-2.51-6.63
Full-Time Employees---970--
Price to Book Ratio2.563.373.203.514.563.38
Return on Assets7.297.056.245.242.65-1.11
Return on Equity18.9919.3317.2715.117.83-2.82
Return on Invested Capital2.681.942.372.212.150.72
Quick Ratio2.332.402.522.192.041.96
Current Ratio2.752.913.122.712.582.54

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income35.1524.7129.4927.4926.628.55
Depreciation19.5519.6420.9222.6122.6323.28
Other Funds (Non Cash)11.9510.865.074.76-6.1611.28
Funds from Operations63.4850.2757.9957.2261.8939.58
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital20.306.400.38-26.85-17.8436.24
Income Taxes Payable5.44-1.7714.090.47-12.55-10.89
Cash from Operating Activities83.7956.6758.3830.3744.0575.81
Capital Expenditures-13.50-3.05-11.32-1.40-6.16-6.91
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-13.50-3.05-11.32-1.40-6.16-6.91
Cash Dividends Paid0.000.000.000.00-0.34-0.41
Preferred Dividends (Cash Flow)0.000.000.000.00-0.34-0.41
Change in Capital Stock-5.69-0.51-17.55-0.578.750.69
Repurchase of Common Pref Stock-7.91-0.81-19.75-0.61-1.04-0.55
Sale of Common Pref Stock2.220.312.200.049.791.24
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-4.06-4.06-4.06-4.06-2.03-2.03
Change in Long Term Debt-4.06-4.06-4.06-4.06-2.03-2.03
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-4.06-4.06-4.06-4.06-2.03-2.03
Net Financing Active Other Cash Flow-0.08-0.080.000.00-0.030.00
Other Financing Activities Uses-0.08-0.080.000.00-0.030.00
Cash from Financing Activities-9.83-4.65-21.62-4.646.34-1.75
Exchange Rate Effect0.090.070.16-1.350.580.84
Net Change in Cash60.5549.0325.5922.9844.8168.00
Free Cash Flow70.2853.6252.3029.1237.9571.80
Price to Free Cash Flow7.6710.518.7010.1012.4810.70

Revenue breakdown

Generic pharmaceutical products2024: 301.00M 2025: 384.11M
Sales of Cortrophin Gel2024: 198.09M 2025: 347.78M
Sales of Established Brands2024: 64.74M 2025: 61.31M
Sales of ILUVIEN and YUTIQ2024: 31.51M 2025: 74.87M
Sales of Royalties and Other Pharmaceutical Services2024: 19.03M 2025: 15.30M
Non-US2024: 9.39M 2025: 30.92M
United States2024: 604.99M 2025: 852.44M
Generics and Other2024: 320.03M 2025: 399.43M
Rare Disease and Brands2024: 294.34M 2025: 483.93M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3017.76%3.6M20.2M385.02K
2026-10-1517.21%3.5M20.2M377.04K
2026-09-3017.30%3.5M20.2M371.59K
2026-09-1512.34%2.5M20.2M349.80K
2026-08-3116.68%3.4M20.2M342.33K
2026-08-1416.99%3.4M20.1M337.03K
2026-07-3111.71%2.3M19.9M339.70K
2026-07-1516.91%3.4M19.9M345.09K
2026-06-3017.26%3.4M19.9M359.86K
2026-06-1516.06%3.2M19.9M347.04K
2026-05-2916.63%3.3M20.0M373.60K
2026-05-1518.12%3.6M20.0M370.39K
2026-04-3017.80%3.6M20.0M346.90K
2026-04-1517.90%3.5M19.5M385.01K
2026-03-3118.29%3.6M19.6M423.07K
2026-03-1318.39%3.6M19.6M452.59K
2026-02-2718.00%3.5M19.6M432.67K
2026-02-1317.47%3.4M19.6M461.17K
2026-01-3017.93%3.5M19.4M472.94K
2026-01-1515.20%2.9M19.4M456.17K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call35.0034.5039.000.004.2790.000.000.955-0.1910.011
call40.0029.5034.000.003.6310.000.000.946-0.1850.012
call45.0024.5029.000.003.2240.000.000.936-0.1780.014
call50.0019.5023.500.002.2690.000.000.922-0.1690.016
call55.0014.5018.400.001.7850.000.000.903-0.1580.019
call60.0010.0012.909.501.0753.000.000.878-0.1440.023
call65.004.808.405.000.9961.000.000.822-0.1240.029
call70.001.203.804.000.6173.000.000.608-0.2030.043
call75.000.051.550.980.6339.000.000.356-0.1600.042
call80.000.001.850.170.95132.000.000.259-0.1950.036
call85.000.004.900.101.2202.000.000.216-0.2260.033
call90.000.001.800.351.4533.000.000.191-0.2490.031
call95.000.004.900.451.5932.000.000.160-0.2440.027
call1000.004.900.051.7844.000.000.147-0.2580.026
call1050.004.900.251.9504.000.000.138-0.2700.025
call1100.004.900.002.1080.000.000.130-0.2810.024
put35.000.004.900.003.0980.000.00-0.043-0.1770.010
put40.000.001.150.002.6550.000.00-0.054-0.1810.012
put45.000.000.950.002.1750.000.00-0.061-0.1650.014
put50.000.001.950.001.8050.000.00-0.078-0.1640.016
put55.000.002.550.001.4220.000.00-0.097-0.1520.019
put60.000.002.950.651.0661.000.00-0.125-0.1360.023
put65.000.050.801.000.71517.000.00-0.178-0.1160.029
put70.000.553.301.350.92616.000.00-0.400-0.1950.043
put75.002.905.505.800.7910.000.00-0.644-0.1520.042
put80.006.6010.500.001.1330.000.00-0.743-0.1870.036
put85.0011.0015.300.001.3680.000.00-0.784-0.2170.033
put90.0016.0020.300.001.6390.000.00-0.809-0.2390.031
put95.0021.0025.500.001.8920.000.00-0.841-0.2330.027
put10026.0030.500.002.0940.000.00-0.853-0.2470.026
put10531.0035.500.002.2790.000.00-0.862-0.2580.025
put11036.2040.500.002.4500.000.00-0.870-0.2680.024

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-058-KCurrent report2026-11-04SEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-10-304Statement of changes in beneficial ownership of securities2026-10-29SEC
2026-10-29144Filing for proposed sale of securities under Rule 144.SEC
2026-10-164Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-15144Filing for proposed sale of securities under Rule 144.SEC
2026-10-134Statement of changes in beneficial ownership of securities2026-10-13SEC
2026-09-304Statement of changes in beneficial ownership of securities2026-09-29SEC
2026-09-164Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-15144Filing for proposed sale of securities under Rule 144.SEC
2026-09-144Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-144Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-11144Filing for proposed sale of securities under Rule 144.SEC
2026-09-014Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-08-274Statement of changes in beneficial ownership of securities2026-08-19SEC
2026-08-273Initial statement of beneficial ownership of securities2026-08-19SEC
2026-08-264Statement of changes in beneficial ownership of securities2026-08-25SEC
2026-08-25144Filing for proposed sale of securities under Rule 144.SEC
2026-08-248-KCurrent report2026-08-19SEC
2026-08-134Statement of changes in beneficial ownership of securities2026-08-13SEC
2026-08-114Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-078-KCurrent report2026-08-07SEC
2026-07-304Statement of changes in beneficial ownership of securities2026-07-29SEC
2026-07-29144Filing for proposed sale of securities under Rule 144.SEC
2026-07-27SCHEDULE 13G/ASEC
2026-07-214Statement of changes in beneficial ownership of securities2026-07-18SEC
2026-07-17S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-07-144Statement of changes in beneficial ownership of securities2026-07-13SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-1000632.68K3
2026-0900698.38K4
2026-0800889.91K4
2026-0700557.71K3
2026-0600707.48K4
2026-05005.69M6
2026-040038.98K1
2026-03002.72M11
2026-02001.29M5
2026-010042.17K1
2025-1200312.65K3
2025-11002.10M4

Institutional holders

Manager% owned
ABSOLUTE INVESTMENT ADVISERS, LLC51.04%
BlackRock, Inc.13.01%
Soleus Capital Management, L.P.3.82%
VANGUARD CAPITAL MANAGEMENT LLC3.69%
STATE STREET CORP3.66%
Bank of New York Mellon Corp3.36%
DIMENSIONAL FUND ADVISORS LP3.17%
TANG CAPITAL MANAGEMENT LLC3.11%
UBS Group AG2.70%
AMERICAN CENTURY COMPANIES INC2.53%

Funds

Fund% owned
ABSOLUTE CONVERTIBLE ARBITRAGE FUND51.54%
iShares Convertible Bond ETF31.21%
Bancroft Fund Ltd8.79%
Ellsworth Growth & Income Fund Ltd8.79%
Fidelity Convertible Securities Fund6.43%
iShares Core S&P Small-Cap ETF4.83%
Gabelli Convertible & Income Securities Fund Inc4.62%
Avantis U.S. Small Cap Value ETF2.81%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.68%
Fidelity Strategic Dividend and Income Fund2.43%

OakChart. ANIP. Cached 15 minutes.